Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Cancer|March 11, 2025
The missing data: A review of gender and sex disparities in researchHannah C Karpel, Linda M Zambrano Guevara, B J Rimel, et al.
Gynecologic Oncology|June 30, 2009
A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancerAngeles Alvarez Secord, Laura J Havrilesky, David M O'Malley, et al.
Frontiers in Oncology|March 4, 2021
SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian CancerArthur-Quan Tran, Stephanie A Sullivan, Leo Li-Ying Chan, et al.
American Journal of Cancer Research|May 15, 2025
Onvansertib inhibits cell proliferation and increases sensitivity to paclitaxel in uterine serous cancer cellsJennifer G Haag, Xiaochang Shen, Nikita Sinha, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 12, 2014
Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancerRebecca Ann Previs, Joshua Kilgore, Renatta Craven, et al.
Molecular and Cellular Biology|April 19, 2017
VprBP/DCAF1 Regulates the Degradation and Nonproteolytic Activation of the Cell Cycle Transcription Factor FoxM1Xianxi Wang, Anthony Arceci, Kelly Bird, et al.
Frontiers in Oncology|August 21, 2023
Orlistat exerts anti-obesity and anti-tumorigenic effects in a transgenic mouse model of endometrial cancerGuangxu Xu, Ziyi Zhao, Weiya Z Wysham, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2024
<i>MAPK14</i> /p38α Shapes the Molecular Landscape of Endometrial Cancer and promotes Tumorigenic CharacteristicsSayali Joseph, Xingyuan Zhang, Gaith Droby, et al.
American Journal of Cancer Research|July 11, 2022
Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancerLindsey Buckingham, Tianran Hao, Jillian O'Donnell, et al.
Pageof 7